Biobetter jointly developed with Ildong, ‘ublituximab’ completed part 1 of Phase 2 clinical trial

Published: 2017-01-24 13:48:05

Updated: 2017-01-24 13:48:05

The development of ‘ublituximab(TG-1101),’ a TG Therapeutics’ monoclonal antibody biobetter, jointly conducted with Ildong Pharmaceutical(CEO Woong-Seup Yoon), passed the part 1 of the Phase 2 clinical trial in the U.S.

Ildong Pharmaceutical quoted the recent announcement of the original developer TG Therapeutics and announced efficacy and safety of the ublituximab’s(TG-1101) multiple sclerosi...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.